Tip:
Highlight text to annotate it
X
Hospira has been operating at the heart of the hospital system for nearly 80 years, serving
hundreds of millions of patients with affordable drugs and delivery systems worldwide.
We are investing $1 billion to ensure that our central role in this system remains vibrant
as we head into the future.
As CEO, I made this investment to ensure Hospira would be able to consistently serve the patients
and hospitals that depend on us.
Today, we are busy putting this investment to use.
Hospira is expanding capacity, increasing redundant capacity, strengthening our supply
chain, modernizing our facilities and streamlining our device portfolio to ensure patients and
customers have access to the products they need.
In addition to our billion dollar investment, we are increasing our funding in research
and development -- and our innovation horizon has never been
brighter.
We're offering hospitals groundbreaking I.V. clinical integration technology that can help
eliminate costs and prevent medication errors.
For patients, we're excited to be able to soon offer more affordable, high-quality biosimilar
drugs here in America, as we've been doing in Europe and Australia for some time.
Hospira puts patients first.
We know that the more we invest, the more money we save patients.
Hospira's introductions of new generic products have helped shave $2 billion in costs from
the U.S. healthcare system in the last two years.
That's why we are building one of the world's largest generic injectable plants to produce
an additional 500 million vials of medicines annually.
That's why we are building new labs and adding new state-of-the-art equipment.
That's why we've hired more than 1,000 new employees in the past year.
This is why I am proud of Hospira.
We are all united in one common purpose: to ensure that patients receive our high-quality,
affordable products in the quantities that they need, when they need them most.
And we're investing $1 billion to prove it.